202 related articles for article (PubMed ID: 15365964)
21. Melatonin corrects reticuloendothelial blockade and iron status in haemodialysed patients.
Labonia W; Rubio D; Arias C
Nephrology (Carlton); 2005 Dec; 10(6):583-7. PubMed ID: 16354241
[TBL] [Abstract][Full Text] [Related]
22. Iron supplementation in haemodialysis--practical clinical guidelines.
Silva J; Andrade S; Ventura H; Santos JP; Colaço S; Oliveira C; Ponce P
Nephrol Dial Transplant; 1998 Oct; 13(10):2572-7. PubMed ID: 9794562
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of oral and intravenous iron therapy in haemodialysis patients.
Jenq CC; Tian YC; Wu HH; Hsu PY; Huang JY; Chen YC; Fang JT; Yang CW
Int J Clin Pract; 2008 Mar; 62(3):416-22. PubMed ID: 17511797
[TBL] [Abstract][Full Text] [Related]
24. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
25. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study.
Schröder O; Mickisch O; Seidler U; de Weerth A; Dignass AU; Herfarth H; Reinshagen M; Schreiber S; Junge U; Schrott M; Stein J
Am J Gastroenterol; 2005 Nov; 100(11):2503-9. PubMed ID: 16279906
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of low-dose i.v. iron therapy in haemodialysis patients.
Park J; Chang JW; Lee JS; Chung HC; Yang WS; Lee SK; Park SK; Park JS
Nephrology (Carlton); 2009 Dec; 14(8):716-21. PubMed ID: 20025679
[TBL] [Abstract][Full Text] [Related]
27. [Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study].
Li H; Wang SX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):457-62. PubMed ID: 19567093
[TBL] [Abstract][Full Text] [Related]
28. Effect of intravenous iron sucrose on oxidative stress in peritoneal dialysis patients.
Saglam F; Cavdar C; Uysal S; Cavdar Z; Camsari T
Ren Fail; 2007; 29(7):849-54. PubMed ID: 17994454
[TBL] [Abstract][Full Text] [Related]
29. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
El-Khatib M; Duncan HJ; Kant KS
Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
[TBL] [Abstract][Full Text] [Related]
30. Erythropoietin and iron.
Sunder-Plassmann G; Hörl WH
Clin Nephrol; 1997 Mar; 47(3):141-57. PubMed ID: 9105761
[TBL] [Abstract][Full Text] [Related]
31. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
Toblli JE; Lombraña A; Duarte P; Di Gennaro F
J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
[TBL] [Abstract][Full Text] [Related]
32. Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients.
Nguyen TV
Am J Health Syst Pharm; 2009 Jun; 66(12):1101-4. PubMed ID: 19498125
[TBL] [Abstract][Full Text] [Related]
33. A comprehensive vision for intravenous iron therapy.
Coyne DW
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
[TBL] [Abstract][Full Text] [Related]
34. [Issues related to iron replacement in dialyzed patients].
Kessler M
Nephrol Ther; 2006 Sep; 2 Suppl 4():S266-73. PubMed ID: 17373269
[TBL] [Abstract][Full Text] [Related]
35. Increased iron requirement in hemodialysis patients on antiplatelet agents or warfarin.
Flint S; Taylor E; Beavis J; Becker GJ; Pedagogos E
Nephron Clin Pract; 2009; 113(1):c38-45. PubMed ID: 19590234
[TBL] [Abstract][Full Text] [Related]
36. Infusion of total dose iron versus oral iron supplementation in ambulatory peritoneal dialysis patients: a prospective, cross-over trial.
Ahsan N
Adv Perit Dial; 2000; 16():80-4. PubMed ID: 11045266
[TBL] [Abstract][Full Text] [Related]
37. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study.
Hsu PY; Lin CL; Yu CC; Chien CC; Hsiau TG; Sun TH; Huang LM; Yang CW
J Nephrol; 2004; 17(5):693-700. PubMed ID: 15593037
[TBL] [Abstract][Full Text] [Related]
38. Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
Tagboto S; Cropper L; Mostafa S; Turner J; Bailey G; Pugh-Clarke K
J Ren Care; 2008 Sep; 34(3):112-5. PubMed ID: 18786076
[TBL] [Abstract][Full Text] [Related]
39. Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose.
Pai AB; Conner T; McQuade CR; Olp J; Hicks P
Biometals; 2011 Aug; 24(4):603-13. PubMed ID: 21229380
[TBL] [Abstract][Full Text] [Related]
40. [Role of iron deficiency in erythropoietin sensitivity in dialysis patients with elevated C-reactive protein].
Martone M; Zanchi R; Panzetta G
G Ital Nefrol; 2003; 20(1):31-7. PubMed ID: 12647284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
